Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Mid-Cap · Goldman Sachs

Goldman Sachs Small/Mid Cap Equity Fund Class A (GMVAX)

Ticker GMVAX · Since 2014-01-31 · · Holdings as of May 31, 2026

Expense ratio
1.17%$117/yr per $10k
5-yr return
+6.6%annualized
1-yr return
+4.7%as of Dec 2024
Net assets
$151.8Mall share classes
Holdings
98

Bottom line

Is GMVAX a good fund? The bottom line

GMVAX is the Class A share class of Goldman Sachs Small/Mid Cap Equity Fund, an actively managed mid-cap mutual fund from Goldman Sachs.

Annual fees run 1.17% — about $117 a year on every $10,000 invested, more expensive than 75% of mid-cap funds we track.

It returned +4.7% over one year, +6.6% a year over five years, +6.6% a year over ten (as of Dec 31, 2024, per its prospectus).

With $152 million in net assets and 98 holdings, its largest position is Macom Technology Solutions Holdings Inc (3.1%) and the top 10 make up 20.8% of the portfolio.

This share class carries a front-end sales charge of up to 5.5%; a no-load class or ETF alternative can avoid it.

What to watch

  • Expensive for its category (1.17%)
  • Front-end sales load up to 5.5%
  • 12b-1 marketing fee of 0.25% a year

Updated Nov 19, 2026

What GMVAX invests in

The Goldman Sachs Small/Mid Cap Equity Fund (the Fund) seeks long-term capital appreciation.

The Fund invests, under normal circumstances, at least 80% of its net assets plus any borrowings for investment purposes (measured at the time of purchase) (Net Assets) in equity securities issued by small-and mid-cap companies. Small-cap and mid-cap companies are companies with relatively small and middle market capitalizations, respectively. As of November 28, 2025, small and mid-cap issuers generally have public stock market capitalizations between $11 million and $44 billion; however, this capitalization range will change over time and with market conditions. The Fund may also invest in securities outside of the then-existing small and mid-cap issuer capitalization range at the time of investment. The Fund seeks to achieve its investment objective by investing, under normal circumstances, in companies that are considered by Goldman Sachs Asset Management, L.P. (the Investment…

From the fund's prospectus (filed Dec 29, 2025).

GMVAX performance

Average annual total returns
1 yr5 yr10 yr
GMVAX+4.7%+6.6%+6.6%
Mid-Cap median+7.9%+8.1%+9.9%

Source: Fund prospectus, as of Dec 31, 2024

Full GMVAX performance history →

What GMVAX costs

On a $10,000 investment, GMVAX's 1.17% expense ratio costs about $117 a year. The prospectus estimates $2,167 in total costs over 10 years (assuming 5% annual returns). The median mid-cap fund charges 0.88%.

See the full GMVAX fee table →

GMVAX top 10 holdings

#Holding% of fund
1Macom Technology Solutions Holdings Inc MTSI3.14%
2Coherent Corp COHR2.79%
3Flex Ltd FLEX2.41%
4Sitime Corp SITM2.15%
5Nvent Electric Plc NVT2.03%
6Lattice Semiconductor Corp LSCC1.95%
7East West Bancorp Inc EWBC1.67%
8Lumentum Holdings Inc LITE1.55%
9Ati Inc ATI1.55%
10Applied Industrial Technologies Inc AIT1.53%

Source: SEC Form N-PORT, period ended May 31, 2026

The top 10 make up 20.8% of the fund. See all top 25 holdings and asset mix →

Alternatives to GMVAX

More funds like GMVAX →

GMVAX FAQ

What is the expense ratio of GMVAX?
GMVAX's expense ratio is 1.17%, which works out to about $117 a year for every $10,000 invested. The prospectus estimates total costs of $2,167 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is GMVAX a good investment?
It depends on your goals, but the data points to: expensive for its category (1.17%); front-end sales load up to 5.5%; 12b-1 marketing fee of 0.25% a year. This is general information, not personalized advice.
What does GMVAX hold?
GMVAX's largest holdings are Macom Technology Solutions Holdings Inc (3.1%), Coherent Corp (2.8%), Flex Ltd (2.4%), Sitime Corp (2.1%), Nvent Electric Plc (2.0%). It holds 98 positions in total as of May 31, 2026 (SEC Form N-PORT).
What is GMVAX's 5-year return?
GMVAX returned +6.6% a year over the five years ending Dec 31, 2024, and +6.6% a year over ten years. Past performance does not guarantee future results.
Does GMVAX have a sales load?
Yes. GMVAX has a maximum front-end sales charge of 5.5%.
Who manages GMVAX?
GMVAX is offered by Goldman Sachs through Goldman Sachs Trust.